ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in Dynamic/Adaptive Supramolecular Self-Assembly: From Molecular Design to Stimuli-Responsive Control.Macromolecular rapid communications · 2026Pooled it
- Stimuli-responsive nanogels as intelligent nanocarriers for tumor microenvironment-triggered anticancer drug delivery.Discover nano · 2026Review
- Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The ultimate goal of cancer theranostics is to deliver imaging agents and therapeutic cargo to tumor sites when and where they are required. "Smart" systems─including targeted and tailored releases with excellent spatial, temporal, and dosage control─should be developed. Supramolecular interactions with dynamic, reversible, and directional features enable the design of biomaterials with ordered architectures, tailored morphologies, multiple types of cargo, and controllable functions. Such supramolecular biomaterials are good candidates for oncology applications, as they optimize therapeutic efficacy while minimizing systemic adverse effects. This review summarizes recent advances in intelligent supramolecular biomaterials, with a specific focus on their spatiotemporal control in cancer theranostics. These biomaterials exploit endogenous and exogenous stimuli to trigger their morphological transformation. In particular, their construction approach and working mechanism, which are crucial in guiding tumor theranostics, are elaborated. Furthermore, the significant challenges in clinical translation and future perspectives for such biomaterials are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.